<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011669</url>
  </required_header>
  <id_info>
    <org_study_id>DSPCLAT-003</org_study_id>
    <nct_id>NCT05011669</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia</brief_title>
  <official_title>The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia: A Multi-Center, Prospective, Open-Label Study for 6 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment&#xD;
      with acute phase patients with schizophrenia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 16, 2021</start_date>
  <completion_date type="Anticipated">June 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of discontinuation due to adverse events</measure>
    <time_frame>during the 6 weeks of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Latuda® 40mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Latuda® 80mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.</description>
    <arm_group_label>Latuda® 40mg/d</arm_group_label>
    <arm_group_label>Latuda® 80mg/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects meet ICD10 criteria for a primary diagnosis of schizophrenia;&#xD;
&#xD;
          -  Subjects have a score ≥ 4 on the CGI-S at Screening and Baseline;&#xD;
&#xD;
          -  Subjects have a PANSS total score ≥ 70 and ≤ 120 at Screening and Baseline, with a&#xD;
             score 4 (moderate) or higher in 2 or more items on the following PANSS items:&#xD;
             delusions, conceptual disorganization, hallucinations, unusual thought content and&#xD;
             suspiciousness;&#xD;
&#xD;
          -  Subjects with acute (including recurrence /relapse and first episode) phase patients&#xD;
             with schizophrenia;&#xD;
&#xD;
          -  Ability to understand the contents of interview and provide written informed consent&#xD;
             (If subject is unable to sign, subject's legal guardian or impartial witness shall&#xD;
             sign the informed consent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with severe or unstable physical diseases (including but not limited to&#xD;
             severe or unstable cardiovascular diseases, cerebrovascular diseases, liver and kidney&#xD;
             diseases) determined by the investigators;&#xD;
&#xD;
          -  Subjects had a history of stomach or intestinal surgery or any other condition that&#xD;
             could interfere with absorption, distribution, metabolism, or excretion of&#xD;
             medications;&#xD;
&#xD;
          -  Based on the judgement of investigators, subject has a history of refractory psychosis&#xD;
             and/or subject has been treated with clozapine (for any reason) within 4 months of&#xD;
             baseline;&#xD;
&#xD;
          -  Subjects has used long-term antipsychotic drugs, e.g. Haloperidol decanoate injection,&#xD;
             Fluphenazine decanoate injection, Risperidone microspheres injection, Paliperidone&#xD;
             palmitate injection, Paliperidone palmitate injection (3M), in the following time&#xD;
             prior to the enrolment;&#xD;
&#xD;
          -  Subjects is at risk of suicide or self-mutilation behaviours or the act of endangering&#xD;
             others, or other corresponding characteristic behaviour, or a history of suicide;&#xD;
&#xD;
          -  Female subjects were pregnant (positive pregnancy test at screening) or breast-feeding&#xD;
             or planning pregnancy for the duration of the study, or the partners of male subjects&#xD;
             were planning pregnancy for the duration of the study;&#xD;
&#xD;
          -  Need to use of disallowed concomitant therapy which is specified in the protocol;&#xD;
&#xD;
          -  History of severe allergy or hypersensitivity;&#xD;
&#xD;
          -  Currently has severe liver function impairment, or serum alanine aminotransferase&#xD;
             (ALT) or aspartate aminotransferase (AST) level ≥3 times the upper limit of normal&#xD;
             value;&#xD;
&#xD;
          -  Creatinine clearance rate &lt; 50mL/min Creatinine clearance rate*100%= Male: (140 - Age)&#xD;
             x Weight(kg)/Serum creatinine (mg/dL) x 72 Female: 0.85*(140 - Age) x Weight(kg)/Serum&#xD;
             creatinine (mg/dL) x 72&#xD;
&#xD;
          -  A history of malignant tumors (including benign pituitary tumors);&#xD;
&#xD;
          -  Any chronic organic disease of the central nervous system (excluding schizophrenia),&#xD;
             such as CNS related tumors and inflammation, active seizures, vascular disease,&#xD;
             Parkinson's disease, Alzheimer's disease, or other forms of dementia, myasthenia&#xD;
             gravis, and other degenerative diseases. A history of mental retardation or persistent&#xD;
             neurological symptoms caused by severe head injury;&#xD;
&#xD;
          -  Subjects received electroconvulsive therapy (ECT) within 90 days prior to screening,&#xD;
             or were expected to require ECT during the study;&#xD;
&#xD;
          -  A history of neuroleptic malignant syndrome;&#xD;
&#xD;
          -  Severe tardive dyskinesia, severe dystonia, or any other severe dyskinesia;&#xD;
&#xD;
          -  Angioedema occurred after previous administration of lurasidone;&#xD;
&#xD;
          -  The subject is participating in or has participated in other clinical trials,&#xD;
             including the use of commercially available drugs or medical devices, within 30 days&#xD;
             prior to the signing of the informed consent;&#xD;
&#xD;
          -  Patients who had previously participated in a clinical study of lurasidone;&#xD;
&#xD;
          -  Any other conditions judged by the investigators that not suitable to participate in&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

